Variation inPCSK9andHMGCRand Risk of

New England Journal of Medicine
375, 2144-2153
DOI: 10.1056/nejmoa1604304

Citation Report

#	Article	IF	Citations
1	The future of epidemiology: methods or matter?. International Journal of Epidemiology, 2016, 45, 1699-1716.	0.9	8
3	Bococizumab for the treatment of hypercholesterolaemia. Expert Opinion on Biological Therapy, 2017, 17, 237-243.	1.4	20
4	PCSK9 inhibition and the global diabetes epidemic. Diabetologia, 2017, 60, 751-752.	2.9	0
5	Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy. Journal of the American College of Cardiology, 2017, 69, 483-485.	1.2	3
6	A New Approach to PCSK9 Therapeutics. Circulation Research, 2017, 120, 1063-1065.	2.0	16
7	Alirocumab for the treatment of hypercholesterolemia. Expert Opinion on Biological Therapy, 2017, 17, 633-643.	1.4	23
8	When Will Mendelian Randomization Become Relevant for Clinical Practice and Public Health?. JAMA - Journal of the American Medical Association, 2017, 317, 589.	3.8	69
9	Cost Effectiveness of Nonstatin-to-Statin Therapy. Journal of the American College of Cardiology, 2017, 69, 1995.	1.2	1
10	Reply. Journal of the American College of Cardiology, 2017, 69, 1994-1995.	1.2	0
11	Targeting lowâ€density lipoprotein cholesterol with <scp>PCSK9</scp> inhibitors. Internal Medicine Journal, 2017, 47, 856-865.	0.5	18
12	Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish. Diabetes, 2017, 66, 2054-2058.	0.3	28
13	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	1.0	2,292
14	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. Diabetes, 2017, 66, 2310-2315.	0.3	20
15	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association, 2017, 6, .	1.6	66
16	A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. New England Journal of Medicine, 2017, 376, e38.	13.9	25
17	PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. BioDrugs, 2017, 31, 167-174.	2.2	14
18	Letter by Koh Regarding Article, â€œPleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin) Tj ETQq0 0 0 rgBT /Overlock 1	1.6	1
19	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. American Journal of Cardiovascular Drugs, 2017, 17, 447-452.	1.0	2

#	Article	IF	Citations
20	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. The Cochrane Library, 2017, 4, CD011748.	1.5	93
21	Human genetics as a model for target validation: finding new therapies for diabetes. Diabetologia, 2017, 60, 960-970.	2.9	19
22	Will genetic studies deliver the next generation of cardioprotective therapies?. European Journal of Preventive Cardiology, 2017, 24, 489-491.	0.8	1
23	Leveraging Human Genetics to Understand the Relation of LDL Cholesterol with Type 2 Diabetes. Clinical Chemistry, 2017, 63, 1187-1189.	1.5	4
24	Vaccination to prevent atherosclerotic cardiovascular diseases. European Heart Journal, 2017, 38, 2508-2510.	1.0	12
25	PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?. Heart, 2017, 103, 1670-1679.	1.2	21
26	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nature Reviews Cardiology, 2017, 14, 577-590.	6.1	443
27	Mendelian randomisation in cardiovascular research: an introduction for clinicians. Heart, 2017, 103, 1400-1407.	1.2	126
28	Investigational therapies for hypercholesterolemia. Expert Opinion on Investigational Drugs, 2017, 26, 603-617.	1.9	4
29	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. International Journal of Cancer, 2017, 140, 2701-2708.	2.3	76
30	Can <scp>LDL</scp> cholesterol be too low? Possible risks of extremely low levels. Journal of Internal Medicine, 2017, 281, 534-553.	2.7	69
31	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	13.9	4,179
32	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	13.9	510
33	PCSK9 inhibition and diabetes: turning to Mendel for clues. Lancet Diabetes and Endocrinology,the, 2017, 5, 78-79.	5.5	3
34	Predicting the benefits and risks of PCSK9 inhibition. Nature Reviews Endocrinology, 2017, 13, 65-65.	4.3	0
35	HMGCR and PCSK9 variants and cardiovascular risk. Nature Reviews Cardiology, 2017, 14, 66-66.	6.1	5
36	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	9.4	470
37	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 1448-1457.	0.6	48

#	Article	IF	Citations
38	Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisinâ€“kexin type 9 inhibitor clinical trials. Current Opinion in Lipidology, 2017, 28, 522-523.	1.2	5
39	PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Current Atherosclerosis Reports, 2017, 19, 49.	2.0	31
40	The shape of things to come in lipid management: a feast of reason. Current Opinion in Lipidology, 2017, 28, 449-451.	1.2	0
41	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1069.	3.0	119
42	Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression. Metabolism: Clinical and Experimental, 2017, 76, 32-41.	1.5	38
43	Evolocumab in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 785-788.	13.9	31
44	Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. Aids, 2017, 31, 2367-2376.	1.0	19
45	Methylglyoxal attenuates insulin signaling and downregulates the enzymes involved in cholesterol biosynthesis. Molecular BioSystems, 2017, 13, 2338-2349.	2.9	11
46	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 941-950.	5.5	452
47	Lipid lowering agents of natural origin: An account of some promising chemotypes. European Journal of Medicinal Chemistry, 2017, 140, 331-348.	2.6	25
48	Efficacy and safety of alirocumab in insulinâ€treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DMâ€INSULIN</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	2.2	105
49	Association of a 3â€² untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women. Aids, 2017, 31, 2483-2492.	1.0	6
50	Increasing Lipolysis and Reducing Atherosclerosis. New England Journal of Medicine, 2017, 377, 280-283.	13.9	20
51	Navigating the Future of Cardiovascular Drug Developmentâ€”Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovascular Drugs and Therapy, 2017, 31, 445-458.	1.3	8
52	Vitamin D, Hypertension, and Ischemic Stroke in 116 655 Individuals From the General Population. Hypertension, 2017, 70, 499-507.	1.3	37
53	PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke. Circulation: Cardiovascular Genetics, 2017, 10, e001632.	5.1	63
54	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. European Journal of Preventive Cardiology, 2017, 24, 1870-1877.	0.8	55
55	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. American Journal of Cardiology, 2017, 120, 1521-1527.	0.7	36

#	Article	IF	Citations
56	Evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Biological Therapy, 2017, 17, 1-15.	1.4	5
57	Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Metaâ€Analysis of 35 Randomized Controlled Trials. Journal of the American Heart Association, 2017, 6, .	1.6	147
58	Recent Developments in Mendelian Randomization Studies. Current Epidemiology Reports, 2017, 4, 330-345.	1.1	553
59	Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. Expert Review of Cardiovascular Therapy, 2017, 15, 923-932.	0.6	10
60	Letter by Koh Regarding Article, â€œFactorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolismâ€• Circulation, 2017, 136, 118-119.	1.6	0
61	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2017, 18, 1243-1260.	0.9	35
62	Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?. Expert Review of Cardiovascular Therapy, 2017, 15, 491-494.	0.6	8
63	Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology, 2017, 18, 147.	0.8	12
64	Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovascular Diabetology, 2017, 16, 38.	2.7	66
65	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular Diabetology, 2017, 16, 70.	2.7	25
66	Effect of ezetimibe add-on therapy over 52Âweeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease, 2017, 16, 122.	1.2	16
67	Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. International Journal of Epidemiology, 2017, 46, 2078-2089.	0.9	123
68	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2017, 318, 947.	3.8	247
69	Analysis of genes to predict the effects of proprotein convertase subtilisin/kexin type 9-inhibitors and statins. Cardiovascular Research, 2017, 113, e8-e9.	1.8	1
70	Statins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link. Frontiers in Pharmacology, 2017, 8, 372.	1.6	25
71	Evolocumab and clinical outcomes in patients with cardiovascular disease. Journal of the Royal College of Physicians of Edinburgh, The, 2017, 47, 153-155.	0.2	12
72	Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events. Korean Circulation Journal, 2017, 47, 432.	0.7	18
73	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug Design, Development and Therapy, 2017, Volume 11, 2121-2129.	2.0	10

#	Article	IF	Citations
74	Diverse type 2 diabetes genetic risk factors functionally converge in a phenotype-focused gene network. PLoS Computational Biology, 2017, 13, e1005816.	1.5	15
75	Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges. PLoS Genetics, 2017, 13, e1006944.	1.5	191
76	Shared genetic regulatory networks for cardiovascular disease and type 2 diabetes in multiple populations of diverse ethnicities in the United States. PLoS Genetics, 2017, 13, e1007040.	1.5	82
77	Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. Diabetes, Obesity and Metabolism, 2018, 20, 1632-1641.	2.2	15
78	Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes and Metabolism, 2018, 44, 508-513.	1.4	40
79	Effects of Different Weight Loss Approaches on CVD Risk. Current Atherosclerosis Reports, 2018, 20, 27.	2.0	31
80	From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. Cardiovascular Research, 2018, 114, 1192-1208.	1.8	64
81	A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. Cell Reports, 2018, 23, 327-336.	2.9	76
82	Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. European Heart Journal, 2018, 39, 354-359.	1.0	43
83	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levelsâ€"The zero-LDL hypothesis. Journal of Clinical Lipidology, 2018, 12, 292-299.e3.	0.6	51
84	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. Pharmacological Research, 2018, 130, 1-11.	3.1	22
85	Alirocumab vs usual lipidâ€lowering care as addâ€on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€DYSLIPIDEMIA randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1479-1489.	2.2	76
86	Mice Fed a Highâ€Cholesterol Diet Supplemented with Quercetinâ€3â€Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas. Molecular Nutrition and Food Research, 2018, 62, e1700729.	1.5	29
87	PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. Postgraduate Medicine, 2018, 130, 287-298.	0.9	8
88	Hypolipidemic Drugs and Diabetes Mellitusâ€"Mechanisms and Data From Genetic Trials. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 187-191.	1.0	5
89	Hypertension with diabetes mellitus complications. Hypertension Research, 2018, 41, 147-156.	1.5	86
90	Effects of evolving lipid-lowering drugs on carbohydrate metabolism. Diabetes Research and Clinical Practice, 2018, 137, 1-9.	1.1	2
91	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs, 2018, 78, 215-229.	4.9	33

#	Article	IF	Citations
92	LDL cholesterol: How low to go?. Trends in Cardiovascular Medicine, 2018, 28, 348-354.	2.3	12
93	The year in cardiology 2017: prevention. European Heart Journal, 2018, 39, 345-353.	1.0	3
94	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
95	Pharmacogenomics of blood lipid regulation. Pharmacogenomics, 2018, 19, 651-665.	0.6	3
96	Response by Labos et al to Letter Regarding Article, â€œEvaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regressionâ€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e87-e88.	1.1	1
97	Unexplained reciprocal regulation of diabetes and lipoproteins. Current Opinion in Lipidology, 2018, 29, 186-193.	1.2	17
98	Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits. Circulation Journal, 2018, 82, 937-943.	0.7	15
99	Causal Effect of Lipids and Lipoproteins on Atherosclerosis. Cardiology Clinics, 2018, 36, 203-211.	0.9	26
100	Lipids and Lipoproteins in Risk Prediction. Cardiology Clinics, 2018, 36, 213-220.	0.9	7
101	Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes. Stroke, 2018, 49, 820-827.	1.0	132
102	Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. Journal of Clinical Lipidology, 2018, 12, 711-717.	0.6	22
103	Proprotein convertase subtilisin/kexin type 9. Current Opinion in Cardiology, 2018, 33, 269-275.	0.8	12
104	Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3686-3691.	3.3	76
105	Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. Current Atherosclerosis Reports, 2018, 20, 20.	2.0	62
106	Clinical benefits of evolocumab appear less than hoped â€“ Authors' reply. Lancet, The, 2018, 391, 934-935.	6.3	2
107	PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes, Obesity and Metabolism, 2018, 20, 270-282.	2.2	22
108	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. European Heart Journal, 2018, 39, 1131-1143.	1.0	171
109	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. Journal of Clinical Lipidology, 2018, 12, 130-136.	0.6	44

#	Article	IF	Citations
110	Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. Journal of Clinical Lipidology, 2018, 12, 122-129.e2.	0.6	36
111	Trials and Tribulations of CETP Inhibitors. Circulation Research, 2018, 122, 106-112.	2.0	210
112	A safety evaluation of evolocumab. Expert Opinion on Drug Safety, 2018, 17, 99-106.	1.0	6
113	Using Human â€˜Experiments of Natureâ€™ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. Drug Safety, 2018, 41, 303-311.	1.4	22
114	Statin use and risk for type 2 diabetes: what clinicians should know. Postgraduate Medicine, 2018, 130, 166-172.	0.9	23
115	A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). Journal of Clinical Lipidology, 2018, 12, 162-172.e6.	0.6	42
116	Evaluation of the Pleiotropic Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 262-265.	1.1	32
117	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. European Heart Journal, 2018, 39, 2540-2545.	1.0	113
118	Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase <scp>III ODYSSEY</scp> clinical trials. Diabetic Medicine, 2018, 35, 121-130.	1.2	31
119	How to use Mendelian randomization to anticipate the results of randomized trials. European Heart Journal, 2018, 39, 360-362.	1.0	64
121	Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?. Current Opinion in Lipidology, 2018, 29, 333-339.	1.2	22
122	Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2018, 29, 433-435.	1.2	0
123	Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors. EBioMedicine, 2018, 38, 257-264.	2.7	34
124	Exploring Coronary Artery Disease GWAs Targets With Functional Links to Immunometabolism. Frontiers in Cardiovascular Medicine, 2018, 5, 148.	1.1	10
125	What the diabetes data in the FOURIER trial fail to show. Diabetes, Obesity and Metabolism, 2019, 21, 741-742.	2.2	3
126	Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders. International Journal of Neuropsychopharmacology, 2018, 21, 1076-1078.	1.0	7
127	Usefulness of compounds with monacolin K in a case of statins intolerance. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 268-270.	0.4	2
128	Usefulness of compounds with monacolin K in a case of statins intolerance. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 268-270.	0.1	1

#	Article	IF	Citations
129	Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. Canadian Journal of Cardiology, 2018, 34, 1600-1605.	0.8	29
130	Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. Circulation, 2018, 138, 2499-2512.	1.6	69
131	Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovascular Diabetology, 2018, 17, 155.	2.7	34
132	Reprint of: Impact of Lipids on Cardiovascular Health. Journal of the American College of Cardiology, 2018, 72, 2980-2995.	1.2	17
133	Key aspects of PCSK9 inhibition beyond LDL lowering. Current Opinion in Lipidology, 2018, 29, 453-458.	1.2	10
134	Medicationâ€based versus targetâ€based lipid management. Journal of Diabetes, 2018, 10, 789-792.	0.8	1
135	PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke. Circulation Genomic and Precision Medicine, 2018, 11, e002247.	1.6	0
136	Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke. Circulation Genomic and Precision Medicine, 2018, 11, e002162.	1.6	48
137	Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors. European Cardiology Review, 2018, 13, 9.	0.7	1
138	Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 <scp>ODYSSEY</scp> trials. Diabetic Medicine, 2018, 35, 1742-1751.	1.2	17
139	Association of Genetically Enhanced Lipoprotein Lipaseâ€“Mediated Lipolysis and Low-Density Lipoprotein Cholesterolâ€“Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. JAMA Cardiology, 2018, 3, 957.	3.0	55
140	Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. PLoS Medicine, 2018, 15, e1002642.	3.9	22
141	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2389-2398.	2.2	19
142	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Therapy, 2018, 9, 1317-1334.	1.2	21
143	Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. Diabetologia, 2018, 61, 1748-1757.	2.9	43
144	Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease. Current Cardiology Reports, 2018, 20, 56.	1.3	2
145	Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 995-1010.	1.1	109
147	Endocytosis of lipoproteins. Atherosclerosis, 2018, 275, 273-295.	0.4	65

#	Article	IF	Citations
148	PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Journal of the American Heart Association, 2018, 7, .	1.6	54
149	Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial. Clinical Cardiology, 2018, 41, 1117-1122.	0.7	11
150	Mendelian randomisation in type 2 diabetes and coronary artery disease. Current Opinion in Genetics and Development, 2018, 50, 111-120.	1.5	13
151	TÎ²4 Increases Neovascularization and Cardiac Function in Chronic Myocardial Ischemia of Normo- and Hypercholesterolemic Pigs. Molecular Therapy, 2018, 26, 1706-1714.	3.7	11
152	Scientific Contributions of Population-Based Studies to Cardiovascular Epidemiology in the GWAS Era. Frontiers in Cardiovascular Medicine, 2018, 5, 57.	1.1	7
153	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. Diseases (Basel, Switzerland), 2018, 6, 44.	1.0	3
154	PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Expert Review of Cardiovascular Therapy, 2018, 16, 567-578.	0.6	11
155	Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study. International Journal of Neuropsychopharmacology, 2018, 21, 1067-1075.	1.0	29
156	The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology, 2018, 72, 314-329.	1.2	162
157	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. Clinical Pharmacology and Therapeutics, 2018, 104, 257-268.	2.3	12
158	Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovascular Diabetology, 2018, 17, 48.	2.7	33
159	PCSK9. Circulation Research, 2018, 122, 1420-1438.	2.0	198
160	Impact of Lipids on Cardiovascular Health. Journal of the American College of Cardiology, 2018, 72, 1141-1156.	1.2	272
161	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases (Basel, Switzerland), 2018, 6, 22.	1.0	10
162	Genomic insights into the causes of type 2 diabetes. Lancet, The, 2018, 391, 2463-2474.	6.3	110
163	CETPâ€Inhibition and HDLâ€Cholesterol: A Story of CV Risk or CV Benefit, or Both. Clinical Pharmacology and Therapeutics, 2018, 104, 297-300.	2.3	22
164	Inactivation of the E3 Ubiquitin Ligase IDOL Attenuates Diet-Induced Obesity and Metabolic Dysfunction in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1785-1795.	1.1	22
165	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. American Journal of Health-System Pharmacy, 2018, 75, 747-754.	0.5	2

#	Article	IF	Citations
166	Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. JAMA Cardiology, 2018, 3, 619.	3.0	428
167	PCSK9 in diabetes: sweet, bitter or sour?. European Heart Journal, 2019, 40, 369-371.	1.0	8
168	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. Clinical Pharmacology and Therapeutics, 2019, 105, 568-581.	2.3	6
169	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. European Heart Journal, 2019, 40, 357-368.	1.0	124
170	Strategies to Overcome Residual Risk During Statins Era. Circulation Journal, 2019, 83, 1973-1979.	0.7	27
172	Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. Clinical Therapeutics, 2019, 41, 1508-1521.	1.1	8
173	Anti-androgenic therapy with finasteride in patients with chronic heart failure - a retrospective propensity score based analysis. Scientific Reports, 2019, 9, 10139.	1.6	7
174	PCSK9 inhibitors: what we know, what we should have understood, and what is to come. European Heart Journal, 2022, 43, e29-e31.	1.0	6
175	The fat of the matter: lipoprotein effects of dietary fatty acids vary by body weight status. American Journal of Clinical Nutrition, 2019, 110, 795-796.	2.2	2
176	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	5.5	207
177	Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality. Journal of the American College of Cardiology, 2019, 73, 3102-3114.	1.2	27
178	More aggressive lipid lowering in people with diabetes?. Lancet Diabetes and Endocrinology,the, 2019, 7, 587-589.	5.5	1
179	Efficacy and safety of PCSK9 monoclonal antibodies. Expert Opinion on Drug Safety, 2019, 18, 1191-1201.	1.0	16
180	Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review. Journal of Cellular and Molecular Medicine, 2019, 23, 7946-7960.	1.6	63
181	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5253-5262.	1.8	4
182	Suggested clinical approach for the diagnosis and management of â€˜statin intoleranceâ€™ with an emphasis on muscleâ€related sideâ€effects. Internal Medicine Journal, 2019, 49, 1081-1091.	0.5	15
183	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovascular Disorders, 2019, 19, 240.	0.7	22
184	Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovascular Diabetology, 2019, 18, 144.	2.7	33

#	Article	IF	Citations
186	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	5.8	160
187	Pancreatic PCSK9 and its involvement in diabetes. Journal of Thoracic Disease, 2019, 11, S2018-S2022.	0.6	3
188	Au-delÃ du risque cardiovasculaire : le rÃ1e des lipoprotÃ©ines contenant lâ€™apoB athÃ©rogÃ¨nes dans lâ€™Ã©tiologie du diabÃ¨te de type 2. Medecine Des Maladies Metaboliques, 2019, 13, 129-139.	0.1	3
189	EfficacitÃ© et sÃ©curitÃ© des inhibiteurs de PCSK9 dans le diabÃ¨te. Medecine Des Maladies Metaboliques, 2019, 13, 147-155.	0.1	1
190	Identifying and Validating New Drug Targets for Stroke and Beyond. Circulation, 2019, 140, 831-835.	1.6	7
191	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.4	1,753
192	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1381.	3.8	144
193	A Genetic Approach to the Association Between PCSK9 and Sepsis. JAMA Network Open, 2019, 2, e1911130.	2.8	25
194	PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads. Journal of Clinical Lipidology, 2019, 13, 714-720.	0.6	9
195	Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels. JAMA Cardiology, 2019, 4, 1067.	3.0	104
196	Association of Triglyceride-Lowering LPL Variants and LDL-Câ€“Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2019, 321, 364.	3.8	460
197	Cholesterol-Lowering Agents. Circulation Research, 2019, 124, 364-385.	2.0	45
198	Statin Toxicity. Circulation Research, 2019, 124, 328-350.	2.0	439
199	LDL-C Targets in Secondary Prevention: How Low Should We Go?. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	4
200	Correctly understanding the diabetes data in FOURIER. Diabetes, Obesity and Metabolism, 2019, 21, 2342-2343.	2.2	0
201	New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease. Current Cardiology Reports, 2019, 21, 69.	1.3	13
202	Associations Between Measures of Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Cohort Study and Mendelian Randomization Analysis Using the UK Biobank. Journal of the American Heart Association, 2019, 8, e011638.	1.6	75
203	Genetic Insights for Drug Development in NAFLD. Trends in Pharmacological Sciences, 2019, 40, 506-516.	4.0	52

#	Article	IF	Citations
204	Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients. BMC Medical Genomics, 2019, 12, 80.	0.7	22
205	Proprotein convertase subtilisin/kexin type 9 in kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 1266-1271.	0.4	18
206	Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations. Science China Life Sciences, 2019, 62, 758-770.	2.3	15
207	Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia. Medicine (United States), 2019, 98, e14400.	0.4	29
208	Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians. Indian Heart Journal, 2019, 71, 184-198.	0.2	40
209	Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Preventionã€€â€• A Meta-Analysis of 12 Randomized Trials â€•. Circulation Journal, 2019, 83, 1356-1367.	0.7	6
210	Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. Diabetes, Obesity and Metabolism, 2019, 21, 39-51.	2.2	8
211	Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies. Diabetes, Obesity and Metabolism, 2019, 21, 52-62.	2.2	10
212	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 6-16.	2.2	13
213	Diabetogenic Action of Statins: Mechanisms. Current Atherosclerosis Reports, 2019, 21, 23.	2.0	43
214	The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?. Canadian Journal of Cardiology, 2019, 35, 558-563.	0.8	1
215	Cholesterol metabolism, pancreatic Î²-cell function and diabetes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2149-2156.	1.8	76
216	Effect of Previous Exposure to Malaria on Blood Pressure in Kilifi, Kenya: A Mendelian Randomization Study. Journal of the American Heart Association, 2019, 8, e011771.	1.6	19
217	The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. Current Cardiology Reports, 2019, 21, 18.	1.3	6
218	Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nature Medicine, 2019, 25, 569-574.	15.2	200
219	Mendelian Randomization Study of ACLY and Cardiovascular Disease. New England Journal of Medicine, 2019, 380, 1033-1042.	13.9	216
220	The culprit is the carrier, not the loads: cholesterol, triglycerides and apolipoprotein B in atherosclerosis and coronary heart disease. International Journal of Epidemiology, 2019, 48, 1389-1392.	0.9	37
221	Cardiovascular events, diabetes and guidelines: the virtue of simplicity. Cardiovascular Diabetology, 2019, 18, 42.	2.7	19

#	Article	IF	Citations
222	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. International Journal of Epidemiology, 2019, 48, 1727-1730.	0.9	3
223	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels â€“ experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology, 2019, 26, 930-949.	0.8	64
224	Relative effects of LDL-C on ischemic stroke and coronary disease. Neurology, 2019, 92, e1176-e1187.	1.5	40
225	24th International Symposium on Infections in the Critically Ill Patient. Medical Sciences (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.3	1
226	A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. Npj Genomic Medicine, 2019, 4, 3.	1.7	26
227	The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics. Stroke and Vascular Neurology, 2019, 4, 158-164.	1.5	171
228	Genetic Determinants of Lipids and Cardiovascular Disease Outcomes. Circulation Genomic and Precision Medicine, 2019, 12, e002711.	1.6	83
229	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Survival in Sepsis. Critical Care Medicine, 2019, 47, 489-491.	0.4	2
230	Management of Hyperlipidemia After Stroke. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 93.	0.4	11
231	Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis*. Critical Care Medicine, 2019, 47, 463-466.	0.4	34
233	Proprotein convertase subtilisin/kexin type 9 and lipid metabolism. Current Opinion in Lipidology, 2019, 30, 186-191.	1.2	22
234	Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Current Opinion in Lipidology, 2019, 30, 1-9.	1.2	51
235	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2019, 132, 16-24.	0.6	5
236	Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects. Indian Journal of Clinical Biochemistry, 2019, 34, 444-450.	0.9	5
237	Treating Disease at the RNA Level with Oligonucleotides. New England Journal of Medicine, 2019, 380, 57-70.	13.9	223
238	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. American Journal of Cardiovascular Drugs, 2019, 19, 113-131.	1.0	4
239	PCSK9 inhibitors: clinical evidence and implementation. Nature Reviews Cardiology, 2019, 16, 155-165.	6.1	195
240	Obesity and dyslipidemia. Metabolism: Clinical and Experimental, 2019, 92, 71-81.	1.5	324

#	Article	IF	Citations
241	Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. Frontiers in Cardiovascular Medicine, 2018, 5, 199.	1.1	47
242	Cardiometabolic Polygenic Risk Scores and Osteoarthritis Outcomes: A Mendelian Randomization Study Using Data From the MalmÃ¶ Diet and Cancer Study and the <scp>UK</scp> Biobank. Arthritis and Rheumatology, 2019, 71, 925-934.	2.9	33
243	Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	25
244	Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition. Circulation Genomic and Precision Medicine, 2019, 12, e002335.	1.6	11
245	Inhibiting PCSK9 â€" biology beyond LDL control. Nature Reviews Endocrinology, 2019, 15, 52-62.	4.3	96
246	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. Annual Review of Medicine, 2019, 70, 19-32.	5.0	6
247	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e38-e81.	1.1	431
248	PCSK9 inhibitors and diabetes: Translational biology to clinical practice. Diabetes, Obesity and Metabolism, 2019, 21, 451-453.	2.2	0
249	PCSK9: from biology to clinical applications. Pathology, 2019, 51, 177-183.	0.3	29
250	Factorial Mendelian randomization: using genetic variants to assess interactions. International Journal of Epidemiology, 2020, 49, 1147-1158.	0.9	53
251	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	1.0	4,871
252	Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2020, 27, 1649-1660.	0.8	13
253	A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome. Nature Communications, 2020, 11, 185.	5.8	45
254	Relation of Hypocholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease. American Journal of Cardiology, 2020, 125, 1026-1032.	0.7	1
255	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International Journal of Cardiology, 2020, 299, 289-295.	0.8	1
256	Evolving concepts on the management of dyslipidaemia. Acta Clinica Belgica, 2020, 75, 80-90.	0.5	3
258	Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. American Journal of Cardiovascular Drugs, 2020, 20, 343-353.	1.0	17
259	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. Atherosclerosis, 2020, 293, 49-56.	0.4	21

#	Article	IF	Citations
260	Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study. Pharmacogenomics Journal, 2020, 20, 462-470.	0.9	18
261	LDL Cholesterol and Dysglycemia: an Intriguing Physiological Relationship. Diabetes, 2020, 69, 2058-2060.	0.3	0
262	Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 31-38.	1.8	13
263	Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nature Reviews Rheumatology, 2020, 16, 689-701.	3.5	131
264	Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2372-2378.	1.1	5
265	An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 1199-1205.	1.5	10
266	Efectividad y seguridad del uso de inhibidores de PCSK9 en el tratamiento de la dislipidemia en el paciente con insuficiencia renal. Nefrologia, 2020, 40, 499-505.	0.2	7
267	Commentary: Using human genetics to guide the repurposing of medicines. International Journal of Epidemiology, 2020, 49, 1140-1146.	0.9	3
268	Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects. Atherosclerosis, 2020, 306, 15-21.	0.4	9
269	Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders. Frontiers in Endocrinology, 2020, 11, 556610.	1.5	4
271	The Role of Statins in Current Guidelines. Current Atherosclerosis Reports, 2020, 22, 50.	2.0	17
272	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opinion on Pharmacotherapy, 2020, 21, 2137-2151.	0.9	7
273	Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. Expert Opinion on Biological Therapy, 2020, 20, 1477-1489.	1.4	2
274	Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study. Diabetologia, 2020, 63, 2349-2358.	2.9	28
275	Targeting RNA With AntisenseÂOligonucleotides and SmallÂInterfering RNA in Dyslipidemias. Journal of the American College of Cardiology, 2020, 76, 563-579.	1.2	52
276	White Adipose Tissue Surface Expression of LDLR and CD36 is Associated with Risk Factors for Type 2 Diabetes in Adults with Obesity. Obesity, 2020, 28, 2357-2367.	1.5	14
277	LDL-cholesterol reduction in chronic kidney disease: options beyond statins. Current Opinion in Nephrology and Hypertension, 2020, 29, 480-488.	1.0	3
278	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3613-3682.	1.8	63

#	Article	IF	Citations
279	Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. Atherosclerosis, 2020, 309, 39-46.	0.4	29
280	Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. Journal of the American College of Cardiology, 2020, 76, 1507-1516.	1.2	155
281	Adverse events to PCSK-9 inhibitors: what is the current evidence?. Postgraduate Medical Journal, 2021, 97, 485-486.	0.9	1
282	Polygenic modelling of treatment effect heterogeneity. Genetic Epidemiology, 2020, 44, 868-879.	0.6	6
283	Safety and Tolerability of PCSK9 Inhibitors: Current Insights . Clinical Pharmacology: Advances and Applications, 2020, Volume 12, 191-202.	0.8	20
284	Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease. Nefrologia, 2020, 40, 499-505.	0.2	3
285	Cerebral small vessel disease genomics and its implications across the lifespan. Nature Communications, 2020, 11, 6285.	5.8	89
286	PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. Frontiers in Physiology, 2020, 11, 595819.	1.3	49
287	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 409-417.	1.0	15
288	On the use of Mendelian randomization to assess the consequences of metformin exposure. International Journal of Epidemiology, 2020, 49, 1408-1410.	0.9	1
289	Metabolomics and Proteomics in Type 2 Diabetes. Circulation Research, 2020, 126, 1613-1627.	2.0	81
290	Network Pharmacological Screening of the Active Ingredients and Hypoglycemic Effect of Isodon rubescens in the Treatment of Diabetes. Planta Medica, 2020, 86, 556-564.	0.7	5
291	Transcriptomeâ€wide association studies: a view from Mendelian randomization. Quantitative Biology, 2021, 9, 107-121.	0.3	22
292	New Pharmacological Approaches to Target PCSK9. Current Atherosclerosis Reports, 2020, 22, 24.	2.0	41
293	PCSK9 Inhibitors in Secondary Preventionâ€"An Opportunity for Personalized Therapy. Journal of Cardiovascular Pharmacology, 2020, 75, 410-420.	0.8	11
294	Identification of novel functional CpG-SNPs associated with type 2 diabetes and coronary artery disease. Molecular Genetics and Genomics, 2020, 295, 607-619.	1.0	11
295	Statin Pharmacology Revisited. Cardiovascular Drugs and Therapy, 2020, 34, 225-226.	1.3	0
296	The Effect of Plasma Lipids and Lipidâ€Lowering Interventions on Bone Mineral Density: A Mendelian Randomization Study. Journal of Bone and Mineral Research, 2020, 35, 1224-1235.	3.1	45

#	Article	IF	Citations
297	Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Medicine, 2020, 17, e1003062.	3.9	470
298	Genetic drug target validation using Mendelian randomisation. Nature Communications, 2020, 11, 3255.	5.8	175
299	Model of genetic and environmental factors associated with type 2 diabetes mellitus in a Chinese Han population. BMC Public Health, 2020, 20, 1024.	1.2	7
300	Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes. Neurology, 2020, 95, e353-e361.	1.5	60
301	What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. Cardiology and Therapy, 2020, 9, 59-73.	1.1	16
302	Lower diabetes rate in patients with familial hypercholesterolaemia: What is the link?. European Journal of Preventive Cardiology, 2020, 27, 1647-1648.	0.8	1
303	Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol. Brain, 2020, 143, 597-610.	3.7	51
304	HDL inhibits endoplasmic reticulum stress-induced apoptosis of pancreatic Î²-cells in vitro by activation of Smoothened. Journal of Lipid Research, 2020, 61, 492-504.	2.0	32
305	Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Drug Discovery, 2020, 15, 403-414.	2.5	3
306	Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for longâ€term inhibition. BioFactors, 2020, 46, 367-380.	2.6	46
307	LDL-Cholesterol-Lowering Therapy. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	8
308	Lipid-Modifying Agents, FromÂStatinsÂtoÂPCSK9 Inhibitors. Journal of the American College of Cardiology, 2020, 75, 1945-1955.	1.2	47
309	Targeting LDL cholesterol: Early treatment is key to population health. Atherosclerosis, 2020, 300, 37-38.	0.4	4
310	Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nature Reviews Neurology, 2020, 16, 247-264.	4.9	167
311	The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1342-1351.	2.2	5
312	HDL and pancreatic Î² cells: a SMO-king gun?. Journal of Lipid Research, 2020, 61, 468-469.	2.0	2
313	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. Annual Review of Medicine, 2021, 72, 447-458.	5.0	12
314	Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study. Journal of Lipid Research, 2021, 62, 100044.	2.0	32

#	Article	IF	Citations
315	Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. British Journal of Pharmacology, 2021, 178, 2168-2185.	2.7	7
316	PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia. European Journal of Preventive Cardiology, 2021, 28, 270-271.	0.8	2
317	How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. European Heart Journal, 2021, 42, 2154-2169.	1.0	28
318	Editorial comment: when Mendelian randomization goes astray. Current Opinion in Lipidology, 2021, 32, 79-80.	1.2	3
319	Association between cumulative exposure to different lipid parameters and risk of newly developed carotid plaque. Stroke and Vascular Neurology, 2021, 6, 359-365.	1.5	8
320	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	0.9	90
321	PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study. Archives of Medical Science, 2021, 17, 241-244.	0.4	12
322	Improved lipid target level attainment in patients with peripheral artery disease. Current Vascular Pharmacology, 2021, 19, 634-642.	0.8	0
323	New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. BMC Pharmacology & Toxicology, 2021, 22, 11.	1.0	1
325	Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surfaceâ€expression of LDLR and CD36 and NLRP3 inflammasome. Physiological Reports, 2021, 9, e14721.	0.7	15
326	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	0.9	48
327	Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nature Reviews Cardiology, 2021, 18, 435-453.	6.1	88
329	Disrupting upstream translation in mRNAs is associated with human disease. Nature Communications, 2021, 12, 1515.	5.8	37
330	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	4.3	19
331	Case report: 68 yo Chinese-American woman with high HDL-C and ischemic stroke attributed to intracranial atherosclerotic stenosis. Journal of Clinical Lipidology, 2021, 15, 248-254.	0.6	0
332	New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B. Journal of the American College of Cardiology, 2021, 77, 1564-1575.	1.2	49
333	Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia. Endocrinology and Metabolism, 2021, 36, 279-295.	1.3	16
334	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart, 2021, 107, 1369-1375.	1.2	53

#	Article	IF	Citations
335	Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. PLoS Genetics, 2021, 17, e1009525.	1.5	15
336	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. Nature Communications, 2021, 12, 2182.	5.8	17
337	Effects of selenium on coronary artery disease, type 2 diabetes and their risk factors: a Mendelian randomization study. European Journal of Clinical Nutrition, 2021, 75, 1668-1678.	1.3	14
338	Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). Hellenic Journal of Cardiology, 2022, 63, 22-31.	0.4	2
339	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.4	83
340	New Trends in Dyslipidemia Treatment. Circulation Journal, 2021, 85, 759-768.	0.7	16
341	Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors. Scientific Reports, 2021, 11, 11450.	1.6	12
342	A phenome-wide association study of genetically mimicked statins. BMC Medicine, 2021, 19, 151.	2.3	16
343	A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes. JAMA Network Open, 2021, 4, e2112820.	2.8	16
344	The risk of ischemic stroke and hemorrhagic stroke in Chinese adults with low-density lipoprotein cholesterol concentrations <â€‰70â€‰mg/dL. BMC Medicine, 2021, 19, 142.	2.3	11
345	Mendelian Randomization Analysis as a Tool to Gain Insights into Causes of Diseases: A Primer. Journal of the American Society of Nephrology: JASN, 2021, 32, 2400-2407.	3.0	32
346	Current Practices and Gaps in Management of Dyslipidemia in Type 2 Diabetes Mellitus (T2DM) in Accordance with American Diabetes Association (ADA) Guidelines: A Subset Analysis from a Real-World, Cross-Sectional Observational Study (LEADD Study). Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 2693-2700.	1.1	6
347	Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. Atherosclerosis, 2021, 326, 47-55.	0.4	18
348	The year 2020 in Atherosclerosis. Atherosclerosis, 2021, 326, 35-44.	0.4	1
349	Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives. The Lancet Healthy Longevity, 2021, 2, e317-e326.	2.0	41
350	Working towards full eradication of lipid-driven cardiovascular risk?. Netherlands Heart Journal, 2022, 30, 15-24.	0.3	2
351	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. Open Heart, 2021, 8, e001710.	0.9	1
352	PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. European Heart Journal, 2021, 42, 3078-3090.	1.0	50

#	Article	IF	Citations
354	Substantial PCSK9 inactivation in Î²-cells does not modify glucose homeostasis or insulin secretion in mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158968.	1.2	24
355	Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats. Journal of Diabetes Research, 2021, 2021, 1-11.	1.0	5
356	Anti-HMGCR myopathy. Current Opinion in Rheumatology, 2021, Publish Ahead of Print, 554-562.	2.0	10
357	Mendelian Randomization: Concepts and Scope. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a040501.	2.9	214
358	Genetics of Type 2 Diabetes: Opportunities for Precision Medicine. Journal of the American College of Cardiology, 2021, 78, 496-512.	1.2	12
359	Statins Are Associated With Increased Insulin Resistance and Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2786-2797.	1.1	49
360	Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. PharmacoEconomics - Open, 2022, 6, 277-291.	0.9	3
361	Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol. World Journal of Cardiology, 2021, 13, 472-482.	0.5	0
362	Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106057.	0.7	8
363	Lipoproteins in chronic kidney disease: from bench to bedside. European Heart Journal, 2021, 42, 2170-2185.	1.0	32
364	Letter regarding, â€œAssociation between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analysesâ€• Journal of Cancer Research and Clinical Oncology, 2021, 147, 2171-2173.	1.2	2
365	Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapiesâ€”a Clinical Perspective. Cardiovascular Drugs and Therapy, 2021, 35, 1269-1279.	1.3	13
366	Colesterol LDL, cuanto mÃ¡s bajo mejor. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 16-27.	0.4	16
367	Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction. Journal of Cardiology, 2020, 76, 395-401.	0.8	12
369	Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance. Current Opinion in Lipidology, 2021, 32, 103-111.	1.2	11
386	The promise and reality of therapeutic discovery from large cohorts. Journal of Clinical Investigation, 2020, 130, 575-581.	3.9	9
387	Predictive network modeling in human induced pluripotent stem cells identifies key driver genes for insulin responsiveness. PLoS Computational Biology, 2020, 16, e1008491.	1.5	14
388	Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study. PLoS Medicine, 2017, 14, e1002362.	3.9	90

#	Article	IF	Citations
389	PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort. PLoS ONE, 2020, 15, e0239752.	1.1	9
390	LDL-C plays a causal role on T2DM: a Mendelian randomization analysis. Aging, 2020, 12, 2584-2594.	1.4	14
391	Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors. Current Medicinal Chemistry, 2020, 27, 4494-4521.	1.2	1
392	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. Current Drug Metabolism, 2019, 20, 72-82.	0.7	12
393	A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases. Current Topics in Medicinal Chemistry, 2019, 19, 1790-1817.	1.0	13
394	Effects of Evolocumab on Cardiovascular Events. Current Cardiology Reviews, 2017, 13, 319-324.	0.6	3
395	Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients. Journal of Clinical Medicine, 2020, 9, 244.	1.0	19
396	Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance. Endocrinology and Metabolism, 2020, 35, 480-483.	1.3	3
397	PCSK9 and carbohydrate metabolism: A double-edged sword. World Journal of Diabetes, 2017, 8, 311.	1.3	16
398	Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank. ELife, 2020, 9, .	2.8	23
399	LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue. Journal of Biomedical Research, 2020, 34, 251.	0.7	18
400	Association of Low-Density Lipoprotein With All-Cause and Cause-Specific Mortality Among Us Adults. SSRN Electronic Journal, 0, , .	0.4	0
401	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature Communications, 2021, 12, 5640.	5.8	57
402	Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. Neurology, 2021, 97, e2223-e2235.	1.5	7
403	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. Current Atherosclerosis Reports, 2021, 23, 79.	2.0	23
404	Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study. Frontiers in Nutrition, 2021, 8, 755834.	1.6	6
405	Human Genomics and Drug Development. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a039230.	2.9	16
406	Mulberry Leaf and Radix Astragali Regulates Differentially Expressed Genes and Proteins in the Streptozotocin-Induced Diabetic Mice Liver. Processes, 2021, 9, 1898.	1.3	2

#	Article	IF	Citations
407	HMG-Coenzyme A Reductase as a Drug Target for the Prevention of Ankylosing Spondylitis. Frontiers in Cell and Developmental Biology, 2021, 9, 731072.	1.8	2
408	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. American Journal of Preventive Cardiology, 2021, 8, 100278.	1.3	14
413	Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?. Annals of Translational Medicine, 2018, 6, 60-60.	0.7	0
415	The year in cardiology 2017: prevention. Cardiologia Croatica, 2018, 13, 79-98.	0.0	0
418	PCSK9 inhibitors and diabetes mellitus. Vnitrni Lekarstvi, 2018, 64, 1186-1189.	0.1	4
419	Treating hypercholesterolaemia with evolocumab. Intervencni A Akutni Kardiologie, 2018, 17, 212-217.	0.0	0
422	Novel Therapies for Dyslipidemia. , 0, , .		0
425	ComplicaÃ§Ãµes crÃ´nicas decorrentes do Diabetes mellitus: uma revisÃ£o narrativa de literatura. Research, Society and Development, 2021, 10, e96101421794.	0.0	0
426	Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences, 2021, 22, 11687.	1.8	44
427	Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2798-2801.	1.1	7
428	Recent insights into low-density lipoprotein metabolism and therapy. Current Opinion in Clinical Nutrition and Metabolic Care, 2021, 24, 120-126.	1.3	7
430	Precision Medicine and Cardiovascular Health: Insights from Mendelian Randomization Analyses. Korean Circulation Journal, 2020, 50, 91.	0.7	7
433	PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. Stem Cell Reports, 2021, 16, 2958-2972.	2.3	7
434	Cost-utility analysis of evolocumab in patients with ASCVD in Italy. Global & Regional Health Technology Assessment, 0, 8, 155-167.	0.2	0
436	Cardiology Meets Personalized Lifestyle Medicine. Integrative Medicine, 2017, 16, 12-16.	0.1	0
437	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. Metabolites, 2021, 11, 807.	1.3	17
438	Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. Diabetes Care, 2022, 45, 232-240.	4.3	10
439	An update on emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs, 2021, 26, 363-369.	1.0	4

#	Article	IF	Citations
440	Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?. Cardiovascular Research, 2022, 118, 2919-2931.	1.8	31
441	Effect of Loss-of-Function Genetic Variants in PCSK9 on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function. Diabetes Care, 2022, 45, 251-254.	4.3	1
442	Response to comment on â€œEvaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human geneticsâ€. Science Translational Medicine, 2021, 13, eabf4530.	5.8	1
443	The dawn of a new era of targeted lipid-lowering therapies. European Heart Journal, 2022, 43, 3198-3208.	1.0	48
444	Addressing dyslipidemic risk beyond LDL-cholesterol. Journal of Clinical Investigation, 2022, 132, .	3.9	51
445	An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. Expert Opinion on Drug Metabolism and Toxicology, 2022, , 1-9.	1.5	7
446	Dissecting the ILâ€6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. British Journal of Clinical Pharmacology, 2022, 88, 2875-2884.	1.1	29
447	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes, Obesity and Metabolism, 2022, 24, 868-880.	2.2	38
448	Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS Medicine, 2022, 19, e1003897.	3.9	30
449	Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovascular Diabetology, 2022, 21, 21.	2.7	10
450	Safety issues associated with the clinical application of PCSK9 inhibitors. Cardiology in Review, 2022, Publish Ahead of Print, .	0.6	1
451	Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes. Clinical Therapeutics, 2022, 44, 331-348.	1.1	4
452	Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. PLoS Biology, 2022, 20, e3001547.	2.6	69
454	Circulating Proprotein Convertase Subtilisin/Kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients. BMC Nephrology, 2022, 23, 123.	0.8	3
455	Investigating the effects of statins on ischemic heart disease allowing for effects on body mass index: a Mendelian randomization study. Scientific Reports, 2022, 12, 3478.	1.6	3
456	Insight into the Evolving Role of PCSK9. Metabolites, 2022, 12, 256.	1.3	21
457	Phenotypic Causal Inference Using Genome-Wide Association Study Data: Mendelian Randomization and Beyond. Annual Review of Biomedical Data Science, 2022, 5, 1-17.	2.8	5
458	DihydroflavonoidsÂas BioactiveÂComponents of Penthorum chinense, a Miao Ethnomedicine, against NAFLD through Bile Acid Metabolism Pathway. Chemistry and Biodiversity, 2022, , .	1.0	2

#	Article	IF	Citations
460	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. European Journal of Preventive Cardiology, 2022, 29, 1334-1342.	0.8	16
464	Mendelian randomization in pharmacogenomics: The unforeseen potentials. Biomedicine and Pharmacotherapy, 2022, 150, 112952.	2.5	10
466	Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment. Advances in Experimental Medicine and Biology, 2022, 1372, 119-143.	0.8	5
467	New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. Biomedicines, 2022, 10, 970.	1.4	8
468	Genetic analysis of the PCSK9 locus in psychological, psychiatric, metabolic and cardiovascular traits in UK Biobank. European Journal of Human Genetics, 2022, 30, 1380-1390.	1.4	8
469	Basal metabolic rate and risk of multiple sclerosis: a Mendelian randomization study. Metabolic Brain Disease, 2022, 37, 1855-1861.	1.4	4
470	A Comprehensive Review of PCSK9 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842211001.	1.0	27
471	The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents. International Journal of Molecular Sciences, 2022, 23, 5617.	1.8	2
472	Statin Use in Relation to Intraocular Pressure, Glaucoma, and Ocular Coherence Tomography Parameters in the UK Biobank. , 2022, 63, 31.		7
473	Association of PCSK9 levels and genetic polymorphisms with stroke recurrence and functional outcome after acute ischemic stroke. Annals of Translational Medicine, 2022, 10, 729-729.	0.7	1
474	AMPK Activation, A Target of Metformin, is Associated with the Risk of Psoriasis and its Comorbidities in the UK Biobank: A Mendelian Randomization Study. SSRN Electronic Journal, 0, , .	0.4	0
476	Association of Common and Rare Genetic Variation in the 3â€Hydroxyâ€3â€Methylglutaryl Coenzyme A Reductase Gene and Cataract Risk. Journal of the American Heart Association, 2022, 11, .	1.6	4
477	Molecular and cellular biology of PCSK9: impact on glucose homeostasis. Journal of Drug Targeting, 2022, 30, 948-960.	2.1	8
478	Chasing LDL cholesterol to the bottom â€" PCSK9 in perspective. , 2022, 1, 554-561.		13
479	Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. BMC Medicine, 2022, 20, .	2.3	56
480	Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know. Current Atherosclerosis Reports, 0, , .	2.0	4
482	Safety of Statins and Nonstatins for Treatment of Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, 51, 655-679.	1.2	7
483	PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vascular Health and Risk Management, 0, Volume 18, 555-566.	1.0	9

#	Article	IF	Citations
484	Inclisiran: How Widely and When Should We Use It?. Current Atherosclerosis Reports, 2022, 24, 803-811.	2.0	17
485	The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. , 2022, 1, 2-13.		0
486	PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acidâ€“Based Therapy Era. Current Atherosclerosis Reports, 2022, 24, 779-790.	2.0	5
487	Management of Dyslipidemia after Stroke. Journal of the Korean Neurological Association, 2022, 40, 217-227.	0.0	1
488	Targeted delivery of therapeutic oligonucleotides in pancreatic cancer. Journal of Biology and Medicine, 2022, 6, 001-004.	0.0	0
489	Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?. International Journal of Molecular Sciences, 2022, 23, 9326.	1.8	5
490	Interpreting the Clinical Implications of Drug-Target Mendelian RandomizationÂStudies. Journal of the American College of Cardiology, 2022, 80, 663-665.	1.2	10
491	Pancreatic PCSK9 controls the organization of the Î²-cell secretory pathway via LDLR-cholesterol axis. Metabolism: Clinical and Experimental, 2022, 136, 155291.	1.5	10
492	Hepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia. Cell Reports, 2022, 40, 111259.	2.9	9
493	Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. International Journal of Molecular Sciences, 2022, 23, 9417.	1.8	17
494	Phenotype Harmonization in the GLIDE2 Oral Health Genomics Consortium. Journal of Dental Research, 0, , 002203452211097.	2.5	2
495	Genotypeâ€driven <scp> NPC1L1 </scp> and <scp> PCSK9 </scp> inhibition and reduced risk of periodontitis. Journal of Clinical Periodontology, 0, , .	2.3	2
496	Novel polymorphism of HMGCR gene related to the risk of diabetes in premature tripleâ€vessel disease patients. Journal of Gene Medicine, 0, , .	1.4	1
497	Genetic insights into therapeutic targets for aortic aneurysms: A Mendelian randomization study. EBioMedicine, 2022, 83, 104199.	2.7	13
498	Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease. JAMA Cardiology, 2022, 7, 955.	3.0	21
499	PCSK9 Inhibition: From Current Advances to Evolving Future. Cells, 2022, 11, 2972.	1.8	26
500	Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 138-147.	1.4	14
501	Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease. International Journal of Molecular Sciences, 2022, 23, 9777.	1.8	22

#	Article	IF	Citations
502	Contribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke. Neurology, 2022, 99, .	1.5	9
503	Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis. Cardiovascular Diabetology, 2022, 21, .	2.7	1
504	Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke. Atherosclerosis, 2022, 361, 41-46.	0.4	4
505	Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study. International Journal of Molecular Sciences, 2022, 23, 10418.	1.8	10
506	Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. Neuropsychopharmacology, 2023, 48, 270-280.	2.8	12
507	Statistical methods for cisâ€Mendelian randomization with twoâ€sample summaryâ€level data. Genetic Epidemiology, 2023, 47, 3-25.	0.6	29
508	Novel Target Study to Cure Cardiovascular Disease regarding Proprotein Converse Subtilisin/Kexin Type 9. BioMed Research International, 2022, 2022, 1-13.	0.9	0
509	Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. European Heart Journal, 2023, 44, 129-138.	1.0	74
510	Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book. European Heart Journal, 0, , .	1.0	3
511	Session Three: Innovating Beyond Glucose Control in Diabetes Care. European Medical Journal Diabetes, 0, , 56-69.	4.0	0
512	Can we revive CETP-inhibitors for the prevention of cardiovascular disease?. Current Opinion in Lipidology, 2022, 33, 319-325.	1.2	7
513	Evaluating the role of non-alcoholic fatty liver disease in cardiovascular diseases and type 2 diabetes: a Mendelian randomization study in Europeans and East Asians. International Journal of Epidemiology, 2023, 52, 921-931.	0.9	10
514	Effect of blood lipids and lipid-lowering therapies on osteoarthritis risk: A Mendelian randomization study. Frontiers in Medicine, 0, 9, .	1.2	1
515	PCSK9 Inhibition and Risk of Diabetes: Should We Worry?. Current Atherosclerosis Reports, 2022, 24, 995-1004.	2.0	12
517	Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Identifies Novel Risk Genes for Schizophrenia. Molecular Neurobiology, 2023, 60, 1537-1546.	1.9	2
518	PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and their Future Perspectives. Current Molecular Pharmacology, 2022, 16, .	0.7	0
519	Association of PCSK9 Loss-of-Function Variants With Risk of Heart Failure. JAMA Cardiology, 0, , .	3.0	1
520	Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	2

#	Article	IF	Citations
521	Bayesian network analysis of panomic biological big data identifies the importance of triglyceride-rich LDL in atherosclerosis development. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
522	Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS Medicine, 2023, 20, e1003988.	3.9	12
523	Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs. Pharmaceuticals, 2023, 16, 176.	1.7	0
524	Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. Blood Cancer Journal, 2023, 13, .	2.8	0
525	Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges. International Journal of Molecular Sciences, 2023, 24, 3291.	1.8	3
526	Address Cardiovascular Health in Middle Age. Journal of the American College of Cardiology, 2023, 81, 705-707.	1.2	3
527	Elevated remnant cholesterol increase 6-year type 2 diabetes mellitus onset risk. Clinica Chimica Acta, 2023, 541, 117253.	0.5	2
528	Supplementation with Natto and Red Yeast Rice Alters Gene Expressions in Cholesterol Metabolism Pathways in ApoE-/- Mice with Concurrent Changes in Gut Microbiota. Nutrients, 2023, 15, 973.	1.7	2
529	Specific Forms of Immune-Mediated Necrotizing Myopathies. , 2023, , 73-100.		0
530	Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function. Cardiovascular Research, 2023, 119, 1537-1552.	1.8	2
531	Association of Incident Cardiovascular Disease With Time Course and Cumulative Exposure to MultipleÂRiskÂFactors. Journal of the American College of Cardiology, 2023, 81, 1151-1161.	1.2	12
532	Low-density lipoprotein cholesterol levels are associated with first-phase insulin release. Diabetes Research and Clinical Practice, 2023, 199, 110633.	1.1	0
533	Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes. MÃ¬Å¾narodnij EndokrinologÃ¬Änij Å½urnal, 2023, 19, 53-64.	0.1	0
534	Association of antihypertensive drugs with fracture and bone mineral density: A comprehensive drug-target Mendelian randomization study. Frontiers in Endocrinology, 0, 14, .	1.5	1
535	The effects of blood pressure and antihypertensive drugs on heart failure: A Mendelian randomization study. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 1420-1428.	1.1	1
536	Prevention of Coronary Atherosclerosis. , 2023, , 39-57.		0
537	Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Medicina (Lithuania), 2023, 59, 776.	0.8	3
538	PCSK9 Inhibitors and Coronary Atherosclerosis: Insights From Recent Intravascular Imaging Clinical Trials. Cardiometabolic Syndrome Journal, 0, 3, .	1.0	0

#	Article	IF	Citations
539	Low cholesterol states: clinical implications and management. Expert Review of Endocrinology and Metabolism, 0, , .	1.2	1
548	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. Contemporary Diabetes, 2023, , 821-878.	0.0	0
550	Evolving Therapeutic Targets. , 2024, , 275-280.e1.		0
551	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. , 2024, , 184-192.e1.		0
573	Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes. Current Atherosclerosis Reports, 2023, 25, 931-937.	2.0	1
582	KardiovaskulÃrer Risikofaktor DyslipidÃmie. Springer Reference Medizin, 2023, , 161-174.	0.0	0
584	Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials. American Journal of Cardiovascular Drugs, 2024, 24, 83-102.	1.0	0